CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,954,098 | -29.1% | 4,991,026 | +3.3% | 0.00% | -25.0% |
| Q2 2023 | $153,631,755 | +40.4% | 4,832,707 | +7.8% | 0.00% | +33.3% |
| Q1 2023 | $109,387,710 | -22.6% | 4,484,941 | +0.1% | 0.00% | -25.0% |
| Q4 2022 | $141,370,577 | +19.4% | 4,482,263 | +7.0% | 0.00% | 0.0% |
| Q3 2022 | $118,363,000 | +8.3% | 4,188,371 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $109,260,000 | -8.0% | 4,132,287 | +21.8% | 0.00% | +33.3% |
| Q1 2022 | $118,735,000 | +5.1% | 3,391,415 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $112,972,000 | +13.9% | 3,484,657 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $99,217,000 | +46.0% | 3,363,278 | +26.8% | 0.00% | +50.0% |
| Q2 2021 | $67,959,000 | +351.0% | 2,652,558 | +141.7% | 0.00% | – |
| Q1 2021 | $15,070,000 | -17.0% | 1,097,571 | +0.2% | 0.00% | -100.0% |
| Q4 2020 | $18,162,000 | – | 1,095,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |